BioLife Solutions - BLFS Stock Forecast, Price & News

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.

Analyst Ratings Changes

Several equities analysts have issued reports on BLFS shares. Oppenheimer raised shares of BioLife Solutions from a "market perform" rating to an "outperform" rating in a report on Monday, April 25th. Cowen reduced their target price on shares of BioLife Solutions from $50.00 to $32.00 in a research report on Tuesday, May 10th. Maxim Group reduced their target price on shares of BioLife Solutions from $60.00 to $30.00 in a research report on Thursday, May 12th. Cowen reduced their target price on shares of BioLife Solutions from $50.00 to $32.00 in a research report on Tuesday, May 10th. Finally, B. Riley reduced their target price on shares of BioLife Solutions from $48.00 to $34.00 in a research report on Tuesday, May 17th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $42.17.

BioLife Solutions Trading Up 4.2 %

BioLife Solutions stock traded up $0.99 during midday trading on Friday, hitting $24.59. 291,011 shares of the stock were exchanged, compared to its average volume of 418,981. BioLife Solutions has a fifty-two week low of $10.40 and a fifty-two week high of $60.67. The stock has a market capitalization of $1.04 billion, a price-to-earnings ratio of -10.93 and a beta of 1.99. The stock's 50-day simple moving average is $16.82 and its 200 day simple moving average is $18.79. The company has a current ratio of 3.55, a quick ratio of 2.53 and a debt-to-equity ratio of 0.02.

BioLife Solutions (NASDAQ:BLFS - Get Rating) last released its quarterly earnings data on Monday, May 9th. The medical equipment provider reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.06). BioLife Solutions had a negative return on equity of 7.54% and a negative net margin of 64.09%. The firm had revenue of $36.22 million for the quarter, compared to analyst estimates of $37.87 million. During the same quarter in the previous year, the business posted $0.01 earnings per share. On average, equities analysts anticipate that BioLife Solutions will post -0.67 EPS for the current year.

Insider Buying and Selling

In related news, COO Greef Roderick De sold 9,158 shares of the firm's stock in a transaction dated Tuesday, July 12th. The shares were sold at an average price of $15.79, for a total transaction of $144,604.82. Following the completion of the sale, the chief operating officer now directly owns 124,458 shares in the company, valued at $1,965,191.82. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other BioLife Solutions news, COO Greef Roderick De sold 9,158 shares of BioLife Solutions stock in a transaction dated Tuesday, July 12th. The shares were sold at an average price of $15.79, for a total transaction of $144,604.82. Following the completion of the sale, the chief operating officer now directly owns 124,458 shares in the company, valued at $1,965,191.82. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CRO Marcus Schulz sold 4,600 shares of BioLife Solutions stock in a transaction dated Wednesday, August 3rd. The shares were sold at an average price of $20.03, for a total transaction of $92,138.00. Following the sale, the executive now owns 36,218 shares of the company's stock, valued at $725,446.54. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 19,602 shares of company stock worth $330,022. Insiders own 3.30% of the company's stock.